GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs ...
GlaxoSmithKline Pharmaceuticals reports a 16% jump in Q2 net profit to Rs 252 crore, driven by strong sales across segments.
Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.
HONG KONG SAR - Media OutReach Newswire - 30 October 2024 - AIM Vaccine (06660.HK), the leader in Chinese mRNA vaccines, announced on 30th October that mRNA respiratory ...
Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...
GlaxoSmithKline said its key brands held ... GSK continues to build on the momentum of its Shingrix Herpes Zoster Vaccine (recombinant, adjuvanted), advancing the adult immunisation category ...
funded by GlaxoSmithKline (GSK), which makes Shingrix, will allow Harris to emulate two target trials using observational data. He’ll examine Shingrix's real-world effectiveness in preventing HZ ...
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...
GlaxoSmithKline places its shingles vaccine ... Another company developing a vaccine for herpes zoster is US biotech Curevo Vaccine, whose adjuvanted subunit vaccine CRV-101 is in early-stage ...